Exhaled breath condensate

Diagmetrics Receives NIH RADx® Award to Advance its Mask Based Diagnostic Platform

Retrieved on: 
Wednesday, August 9, 2023
Condensate, Exhaled breath condensate, Electronics, Disability, Human services, Acceleration, COVID-19, United States Department of Health and Human Services, National Institute of Biomedical Imaging and Bioengineering, MBD, Diagnosis, Medical imaging, Federal, Biomarker, Tech, National Institutes of Health, Bangladesh Technical Education Board, Pandemic, EBC, OTC, Biological engineering, Controversies regarding COVID-19 contracts in the United Kingdom, NIH, Pharmaceutical industry

MADISON, Conn., Aug. 9, 2023 /PRNewswire-PRWeb/ -- DiagMetrics Inc. announced today that it has been awarded Phase 1 funding from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program in support of its Mask-Based Diagnostic (MBD™) for rapid detection of COVID-19 for use by individuals with disabilities. The initial award of $938,784.25 has the potential for Phase 2 funding pending successful completion of Phase 1. The RADx Tech award is funded by National Institute of Biomedical Imaging and Bioengineering (NIBIB) and will help DiagMetrics continue the development and validation of its novel Mask Based Diagnostic platform as it progresses to product commercialization.

Key Points: 
  • The initial award of $938,784.25 has the potential for Phase 2 funding pending successful completion of Phase 1.
  • The RADx Tech award is funded by National Institute of Biomedical Imaging and Bioengineering (NIBIB) and will help DiagMetrics continue the development and validation of its novel Mask Based Diagnostic platform as it progresses to product commercialization.
  • The DiagMetrics' MBD provides a simple way for users with disabilities to perform a COVID-19 test by themselves.
  • "The user simply puts on a mask, presses a button to activate the test, and breathes normally for a few minutes.

Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection

Retrieved on: 
Wednesday, May 17, 2023
Medical Devices, Infectious Diseases, Defense, Health, Contracts, Duke University, Medicine, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Respiratory disease, Organic compound, Infection, Volatile organic compound, COVID, Biomarker, Naval Aviation Warfighting Development Center, Exhaled breath condensate, Risk, Vaccine, FAIMS

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’.

Key Points: 
  • Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’.
  • The ‘EXHALE’ project, focused on the early detection of human infection using volatile organic compounds (VOCs) on breath, will develop a handheld device capable of non-invasive detection of pre-symptomatic respiratory infectious disease.
  • Warfighters routinely operate in remote environments where access to medical personnel is limited and the ability to diagnose infectious disease early is challenging.
  • The portable device by Owlstone will be adapted to work off battery power and detect VOCs present in exhaled breath, filling a gap in infectious disease detection.

Decipher Fat Burning: A Breath Analyzer Achieved Funding Goal on Indiegogo in 1 Hour

Retrieved on: 
Wednesday, March 8, 2023
Burn, Nature, Metanoia, Organic compound, Diabetes, Hybrid Insect Micro-Electro-Mechanical Systems, Oxidative stress, Health, Diet, Lipid metabolism, Volatile organic compound, Needle, Exhaled breath condensate, Analyser, MEMS, Fasting, Medical device, Medical imaging, Indiegogo

SINGAPORE, March 8, 2023 /PRNewswire/ -- Singapore-based Tech startup Metanoia Sensing has announced a new breath analyzer 'MetaNose' to help people monitor their fat (lipid) burning status.

Key Points: 
  • SINGAPORE, March 8, 2023 /PRNewswire/ -- Singapore-based Tech startup Metanoia Sensing has announced a new breath analyzer 'MetaNose' to help people monitor their fat (lipid) burning status.
  • The MetaNose device has been launched on Indiegogo and has reached its funding goal within the first hour.
  • MetaNose is able to tell you how and when your fat burning is activated and elevated.
  • The non-invasive device is the best companion for individuals who are on ketogenic diet, exercising or simply trying to lose fat.

An Innovation to Stop the Spread of COVID, Flu, Colds, and More May Be Right in Front of Your Face

Retrieved on: 
Wednesday, October 19, 2022
National Institute, Disease, Aircraft, Urinary tract infection, Measles, Mumps, Today, Virus, Carrier Global, Air conditioning, COVID, HVAC, Nose, Coronavirus, Technology, Eye, WHO, National Institutes of Health Clinical Center, Harvard University, World, Doctor of Philosophy, DRS, Tuberculosis, Heating, ventilation, and air conditioning, Motion, IP, Patent, University, World Health Organization, Philippine Span Asia Carrier Corporation, Bacteria, Exhaled breath condensate, ACH, HEPA, GLOBE, Vaccination, Atmosphere, Massachusetts Institute of Technology, School, Cough, Television, Ventilation, Yale University

"Today is an important step in a two-year-plus journey for Air-Clenz," explained company Chief Executive Officer Stuart Sheldon.

Key Points: 
  • "Today is an important step in a two-year-plus journey for Air-Clenz," explained company Chief Executive Officer Stuart Sheldon.
  • Air-Clenz can capture and clean an exhaled air breath, cough or sneeze to 99.97% pure in less than 10 seconds.
  • Further, while Air-Clenz utilizes true HEPA filter technology, the patent covers all known possible ways of cleaning and/or purifying indoor and exhaled air.
  • The Air-Clenz approach to business is that of licensing and/or selling its IP, after having invented, developed working prototypes, proven and protected its intellectual property.

Breath Analyzer Global Market Report 2022: Increasing Alcohol Consumption & Rising Related Road Incidents Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 10, 2022
Technology, Other Technology, Color, Substance abuse, COPD, Diagnosis, Potassium dichromate, Carbon monoxide, Smoking, CAGR, Asthma, Cancer, Non-governmental organization, Accident, Degenerative disease, Tuberculosis, Blood, Awareness, Safety, Exhaled breath condensate, Chronic obstructive pulmonary disease, COVID-19, Growth

The "Breath Analyzer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breath Analyzer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global breath analyzer market size reached US$ 2.9 Billion in 2021.
  • Increasing alcohol consumption, along with the rising instances of road accidents caused by the influence of alcohol and other drugs, represent as the key factors driving the growth of the market.
  • Breath analyzers are extensively utilized by law enforcement agencies for the detection of alcohol in the breath and improving road traffic safety.

CHOP Researchers to Lead Department of Defense Project to Measure Mitochondrial Function and Better Detect Mitochondrial Disease

Retrieved on: 
Tuesday, October 4, 2022
Movement, Department of Defense Serum Repository, Nanotechnology, Heart, Assistant, Infection, Hospital, Children's Hospital, University, Children's Hospital of Philadelphia, Traumatic brain injury, Disease, Gene, Health, Department, Mitochondrial disease, Exercise intolerance, Liver, Center, MD, Pediatrics, Mitochondrion, Weakness, PICU, Fatigue, CHOP, Ageing, Sepsis, United States Department of Defense, Falk, Stroke, Program, Pediatric intensive care unit, Exercise, Biomarker, Patient, Diagnosis, Philadelphia, Assistant Secretary of Defense for Health Affairs, Neurodegeneration, Division, Seizure, Disability in Canada, Exhaled breath condensate, Relative energy deficiency in sport, Medical device, Medical imaging, Vaccine, Defense, Child

PHILADELPHIA, Oct. 4, 2022 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have received an $11.85 million Peer Reviewed Medical Research Program (PRMRP) Focused Program Award from the United States Department of Defense to develop and validate minimally invasive or noninvasive diagnostic techniques to quantify mitochondrial function in living people.

Key Points: 
  • "It is deeply exciting to think about the potential impact this work may have on the future of mitochondrial disease diagnosis and care," Falk said.
  • Since the disease has the potential to present in a variety of ways, mitochondrial disease is often very difficult to diagnose or is misdiagnosed entirely.
  • So far, more than 300 genes have been identified that are implicated in the development of mitochondrial disease.
  • Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

Novel Seat Ventilation for Aircraft Significantly Reduces Airborne Virus and Bacteria Transmission, Says University of New Mexico Research

Retrieved on: 
Wednesday, June 8, 2022
General Health, Other Travel, General Automotive, Transportation, Automotive, Travel, Environment, Air, Transport, Automotive Manufacturing, Aerospace, Health, Manufacturing, Aircraft, Physics of Fluids, Infection, Coronavirus, Eye, Boeing 737 Next Generation, COVID, Conference, Research, School, Mechanical, Doctor of Philosophy, 737, International Society, Environment, Sneeze, Travel, Tuberculosis, University, United States Air Force Scientific Advisory Board, Cough, DRS, International Conference on Mechanical Industrial & Energy Engineering, Risk, Technology, Imperial College London, COVID-19, Boeing, Exhaled breath condensate, Aerosol, University of New Mexico, Bacteria, Vaccine, Heating, ventilation, and air conditioning, Airline, Personal protective equipment, Physics, Indoor

The Air-Clenz invention was recently granted U.S. Patent 11,324,850 and covers multi-seated venues and vehicles of all types, including aircraft.

Key Points: 
  • The Air-Clenz invention was recently granted U.S. Patent 11,324,850 and covers multi-seated venues and vehicles of all types, including aircraft.
  • These results were contrasted in simulations utilizing the same parameters, but this time relying on solely the existing aircraft ventilation system.
  • The research showed that cross-infection can occur within the first 20-50 seconds of exhaling an infectious breath, cough, or sneeze on an aircraft.
  • Aircraft cabin air using state-of-the-art ventilation is changed only every 150 seconds on average.

Longitudinal Study Indicates High Exhaled Viral Load Early in the Course of a SARS-CoV-2 Infection

Retrieved on: 
Tuesday, December 21, 2021
Aerosol, Flemish Government, IMEC, KU Leuven, Disease, Silicon, Christmas, Education, Viral load, Public health, Infection, UZ Leuven, Industry, ICT, Artificial intelligence, Health, PCR, Trial of the century, Severe acute respiratory syndrome coronavirus 2, Research, Multimedia, Preprint, Exhaled breath condensate, International, Saliva, Vaccine

A longitudinal study, including unprecedented molecular tests performed on aerosols, reveals that exhaled viral load (the purported measurement of contagiousness) peaks before rapid antigen tests are reliably positive.

Key Points: 
  • A longitudinal study, including unprecedented molecular tests performed on aerosols, reveals that exhaled viral load (the purported measurement of contagiousness) peaks before rapid antigen tests are reliably positive.
  • The findings imply that people can spread the virus early in the course of an infection while their rapid antigen test is negative.
  • This assumption was based on the data from PCR tests with nasopharyngeal swabs, which showed a lower viral load at an early stage of infection.
  • A longitudinal study from KU Leuven, UZ Leuven and imec revealed clear differences in the temporal dynamics of viral load for nasopharyngeal swab, saliva, breath, and antigen tests.

Imec signs licensing agreement with miDiagnostics to commercialize its patented technology for fast and reliable COVID-19 diagnosis based on exhaled breath

Retrieved on: 
Thursday, October 14, 2021
View, Exhaled breath condensate, Digital technology, International, Technology, History, Aerosol, Blood, Saliva, Diagnosis, Industry, Cancer, Silicon, Flemish Government, Knowledge, Education, Infection, Multimedia, Johns Hopkins University, Artificial intelligence, RNA, Health, Public health, PCR, Investment, Company, Fingerstick, CEO, Brussels Airport, Entrepreneurship, Nanofluidic circuitry, Research, ICT, COVID-19, Pharmaceutical industry

"I note with great pride that we have run an impressive course in the past months," says Luc Van den hove, CEO at imec.

Key Points: 
  • "I note with great pride that we have run an impressive course in the past months," says Luc Van den hove, CEO at imec.
  • "We have succeeded in transforming a promising concept and groundbreaking technology into a functional proof-of-concept that has passed both user tests and clinical studies.
  • This is the first time that we have gone this far in the development of our chip technology towards commercialization.
  • The license agreement with miDiagnostics is an important milestone for imec: Our breakthrough technology will help curb the COVID-19 pandemic in the foreseeable future."

Cannabix Technologies Granted U.S. Patent for FAIMS molecular analysis device

Retrieved on: 
Tuesday, August 17, 2021
Company, Canadian Intellectual Property Office, Detection, Gold, CSE, Laboratory, Growth, Technology, GLOBE, Regulation, FAIMS, Research, Law enforcement, United, Spectrometry, Exhaled breath condensate, Intellectual property, THC, Mass spectrometry, Electronics, Workplace, Working dog, Atmospheric pressure, OTC, Method, United States Patent and Trademark Office, Cannabis, IP, Patent

This patent is centered on innovations made by Cannabix with its FAIMS (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer technology.

Key Points: 
  • This patent is centered on innovations made by Cannabix with its FAIMS (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer technology.
  • Cannabix is using its FAIMS technology to detect 9-tetrahydrocannabinol (THC), a non-volatile compound, in breath.
  • The Cannabix FAIMS marijuana breathalyzer device uses ion mobility filtering techniques related to mass spectrometry the gold standard analytical technique for molecular detection.
  • There is no assurance that existing patent pending technologies licensed by the Company will receive patent status by regulatory authorities.